MedDataX Logo

Pharmaco-proteomic Platform to Evaluate Drug Interactions in Liver Transplant Patients

NCT ID: NCT06682325

Last Updated: 2024-11-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

48 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-06-01

Study Completion Date

2025-05-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to enhance the ability to forecast kidney failure in liver transplant patients in the ICU under multidrug treatment by developing a computer platform that integrates mathematical models of drug interactions, proteomics, and clinical data. The main outcomes it aims to develop are:

1. Design the multidrug web computing platform with available information on drug pair interactions (DDIs).
2. Integrate the proteomic and clinical data of liver transplant patients into the IT platform.
3. Implement the multidrug web platform to predict the clinical evolution of liver transplant patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunosuppressive Therapy Optimization: Development of a Population Pharmacokinetic-pharmacodynamic (PK-PD) Model in Liver Transplantation

NCT02877628

Liver Transplantation
COMPLETED

Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients

NCT01760356

End Stage Liver Disease Rejection Infection +3 more
TERMINATED

Validation of Population Pharmacokinetic Model Derived From Healthy Volunteer in Kidney Transplant Recipients

NCT02808065

Kidney Transplantation
UNKNOWN

Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors

NCT00456235

Liver Transplantation
COMPLETED PHASE4

Cefepime Pharmacokinetics in Liver Transplant Recipients in an Intensive Care Unit

NCT00177931

Evidence of Liver Transplantation
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this project is to enhance the ability to forecast kidney failure for liver transplant patients in the ICU by developing a computer platform that integrates mathematical models of drug interactions, proteomics, and clinical data. This integrated platform enables the prediction of the development of AKI in patients who have undergone OLT. Through the integration of mathematical models, the platform captures complex interactions between multiple drugs and proteomics data from patients, contributing to an improved predictive capacity for AKI outcomes.

By leveraging proteomic insights, personalized therapeutic interventions can be devised, promoting safer and more effective treatments. This research seeks to empower medical professionals with comprehensive information to navigate the complex landscape of drug interactions and personalized treatment strategies, ultimately contributing to improved patient outcomes and healthcare practices in the realm of liver transplantation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug-drug Interaction Liver Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Multi-drug interaction

The clinical impact associated with the use of multiple drugs in liver transplant patients during their stay in ICU will be evaluated.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Liver transplant patients undergoing surgery at UC Christus Hospital

Exclusion Criteria

* Patients on renal replacement therapy
* Patients for whom no clinical or pharmacological registry is available
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universidad de Valparaiso

OTHER

Sponsor Role collaborator

Universidad Adolfo Ibañez

UNKNOWN

Sponsor Role collaborator

Pontificia Universidad Catolica de Chile

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nelson Barrera, PhD

Role: PRINCIPAL_INVESTIGATOR

Pontificia Universidad Catolica de Chile

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universidad de Valparaíso

Valparaíso, Región de Valparaíso, Chile

Site Status ACTIVE_NOT_RECRUITING

Hospital ClínicoUC-Christus

Santiago, Santiago Metropolitan, Chile

Site Status RECRUITING

Pontificia Universidad Católica de Chile

Santiago, Santiago Metropolitan, Chile

Site Status ACTIVE_NOT_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Chile

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nelson Barrera, PhD

Role: CONTACT

[email protected]
56987687058

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nelson Barrera, PhD

Role: primary

[email protected]
56987687058

Jaime Retamal, PhD

Role: backup

Nelson Barrera, PhD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

23I10401

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Identification of Drug-drug Interaction Between Tacrolimus and Mycophenolate Mofetil in Healthy Adults
NCT02743247 COMPLETED PHASE1
The Effects of Microbiota Composition on Immunosuppression Protocols in Transplantation
NCT04360031 UNKNOWN
Precision Drug Use of Immunosuppressants Guided by Population Pharmacokinetics/Pharmacodynamic Models in Kidney Transplant Patients
NCT05872815 UNKNOWN
Search for Transcriptional Biomarkers in a Conversion Protocol From Calcineurin Inhibitors to Mycophenolate Mofetil
NCT01321112 UNKNOWN NA
Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients
NCT01288521 COMPLETED PHASE4
Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil After Liver Transplantation
NCT00151632 TERMINATED PHASE3
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
NCT03527238 COMPLETED PHASE2
Pharmaco-economical Study in Kidney Transplantation
NCT01989832 COMPLETED
Pharmacokinetics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus Toxicity
NCT01709136 TERMINATED PHASE2/PHASE3
Pharmacogenetic Study of Tacrolimus in Hepatic Transplant (CYPTAC'H)
NCT01388387 COMPLETED NA
Assessment of the Pharmacokinetic Profile of Tacrolimus Medications and Their Relation to Effectiveness and Safety in Liver Transplant Patients
NCT05744635 RECRUITING
Study Comparing in Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus&Sirolimus
NCT01958190 COMPLETED PHASE4
Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients
NCT00812786 COMPLETED PHASE4
Renal Function Evaluation After Reduction of Cyclosporine A Dose in Renal Transplant Patients
NCT00213590 COMPLETED PHASE3
Polycystic Liver Disease in Kidney Transplant
NCT00934791 TERMINATED NA
Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis
NCT00203281 WITHDRAWN
Investigation of the Steady State Pharmacokinetics of Tacrolimus, Mycophenolate Mofetil and Fluvastatin After Renal Transplantation
NCT00223015 COMPLETED PHASE4
Bayesian Dose Adjustment of Immunosuppressants After Lung Transplantation
NCT00975663 TERMINATED PHASE4
A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients
NCT01625377 COMPLETED PHASE3
Investigation of the Steady State Pharmacokinetics of Sirolimus, Mycophenolat Mofetil and Fluvastatin After Renal Transplantation
NCT00223028 COMPLETED PHASE4
Pre-transplant Assessment of Tacrolimus Blood Level Concentration, as a Predictor of Tacrolimus Dose Requirements After Kidney Transplantation
NCT00297310 COMPLETED PHASE4
Tacrolimus and Daclizumab Versus Tacrolimus and Steroids in Liver Recipients Receiving Sub-optimal Grafts
NCT00321074 COMPLETED PHASE3
Determining Equivalence Dose for Oral Versus Sublingual Administration of Tacrolimus in Hepatic Receptors
NCT02608606 COMPLETED NA
Study of the Pharmacokinetics of Mycophenolate Mofetil in Patients Who Have Undergone Orthotopic Liver Transplantation
NCT00007059 COMPLETED NA
Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma
NCT00355862 COMPLETED PHASE3